ischaemic heart disease
MetadataShow full item record
PublisherEuropean Cardiology Review
JournalEuropean Cardiology Review
AbstractErectile dysfunction (ED) is a common disorder that affects the quality of life of many patients. It is prevalent in more than half of males aged over 60 years. Increasing evidence suggests that ED is predominantly a vascular disorder. Endothelial dysfunction seems to be the common pathological process causing ED. Many common risk factors for atherosclerosis such as diabetes, hypertension, smoking, obesity and hyperlipidaemia are prevalent in patients with ED and so management of these common cardiovascular risk factors can potentially prevent ED. Phosphodiesterase type 5 inhibitors provide short-term change of haemodynamic factors to help initiate and maintain penile erection. They have been shown to be an effective and safe treatment strategy for ED in patients with heart disease, including those with ischaemic heart disease and hypertension.
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
- New treatment options for erectile dysfunction in patients with diabetes mellitus.
- Authors: Basu A, Ryder RE
- Issue date: 2004
- [Sex, erectile dysfunction, and the heart: a growing problem].
- Authors: Görge G, Flüchter S, Kirstein M, Kunz T
- Issue date: 2003 Jun
- Erectile dysfunction for primary care providers.
- Authors: Brien JC, Trussell JC
- Issue date: 2008 Aug
- [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
- Authors: Bryniarski L, Rzepecki M, Klocek M, Wyczołkowski M
- Issue date: 2009
- A systematic review of the association between erectile dysfunction and cardiovascular disease.
- Authors: Gandaglia G, Briganti A, Jackson G, Kloner RA, Montorsi F, Montorsi P, Vlachopoulos C
- Issue date: 2014 May